CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Longterm treatment with pegylated interferon-alfa2b reduces hepatocellular carcinoma incidence and prevents clinical complication in hepatitis C liver cirrhosis–an interim analysis of a multicenter trial
DOI 10.1055/s-2007-967891
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Erhardt, W Böcher, U Heinzel-Pleines, H Wedemeyer, M Dollinger, F Albert, T Witthöft, D Häussinger
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2007
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and aims: Interferons has been shown to inhibit fibrosis progression. This multicenter, randomized, prospective trial investigated the efficacy of low-dose pegylated interferon-alpha 2b (0,35–1µg/kg/wk) given for 3 years to prevent complications of liver cirrhosis. Methods/patients: Patients (N=88) with chronic hepatitis C and histologically proven cirrhosis (Child Pugh Score 5–7) who were non-responsive…
Zitieren
Zitierempfehlung
A Erhardt, W Böcher, U Heinzel-Pleines, H Wedemeyer, M Dollinger, F Albert, T Witthöft, D Häussinger (2007) Longterm treatment with pegylated interferon-alfa2b reduces hepatocellular carcinoma incidence and prevents clinical complication in hepatitis C liver cirrhosis–an interim analysis of a multicenter trial. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-2007-967891
Mit CareLit weiterarbeiten